Introduction
Rozlytrek (entrectinib) is an oral prescription kinase inhibitor used to treat certain cancers associated with specific genetic alterations. It is approved for adults with ROS1-positive metastatic non-small cell lung cancer and for adults and pediatric patients older than 1 month with certain NTRK gene fusion-positive solid tumors.
Rozlytrek targets several receptor tyrosine kinases, including TRKA, TRKB, TRKC, ROS1, and ALK. The medication is available in capsule and oral-pellet forms, with dosing determined by the patient’s condition and, for pediatric patients with NTRK-positive solid tumors, age and body surface area.
Prescription Hope may help eligible patients navigate prescription assistance for Rozlytrek and other medications.
What Is the Rozlytrek Patient Assistance Program?
Unfortunately, many Americans struggle to afford their brand-name medications, such as Rozlytrek.
Pharmaceutical manufacturers understand this and have developed a solution.
Patients may apply for patient assistance programs, which provide brand-name medications at affordable rates. Qualified patients are approved and then receive their medications. All shipments come directly from the manufacturer to the patient’s house or doctor’s office.
However, patient assistance programs have been known to include difficult application processes that require forms, extensive documentation, coordination with healthcare providers and the manufacturer, and more.
Thankfully, Prescription Hope offers a solution.
How Expert Advocates Help Make Rozlytrek More Affordable
Patient-Focused Medication Support
Getting help with prescription costs should feel simple and reassuring. At Prescription Hope, patients can count on trusted prescription assistance support from experienced medication assistance advocates who guide them through every step of the patient assistance program application process, including patients seeking Rozlytrek assistance.
Our caring team takes the administrative burden off your shoulders by completing forms, collecting required documents and signatures, and coordinating with healthcare providers and manufacturers. We manage the details from start to finish so you can spend less time navigating paperwork and more time focusing on your health.
Simplified Access to Specialty Therapies
At Prescription Hope, we make it easier for qualified patients to explore specialty medication affordability with compassionate, personalized support. Our specialty therapy assistance helps simplify access to high-cost prescriptions, including the Rozlytrek specialty medication, so you can spend less time worrying about medication costs and more time focusing on your health and peace of mind.
Ongoing Prescription Assistance
Our ongoing prescription assistance goes beyond the initial application to help qualified patients stay on track with their medications over time. With continued medication assistance from our dedicated patient advocates, you can rely on consistent prescription assistance support for form and document updates, issue resolution, annual renewals, program monitoring, and refill scheduling.
If you are looking for a simpler path to affordable brand-name medications like Rozlytrek, enroll with Prescription Hope today. Our caring team will guide you through the assistance process, manage the details, and help make accessing your prescribed medication feel less overwhelming.
Rozlytrek Price Comparison
vs
Estimated Retail Price*
30-Day Supply
Prescription Hope Price
Per Month, NO Matter The Retail Price
*Source: Drugs.com
Rozlytrek Patient Assistance Eligibility
If you are wondering who qualifies for Rozlytrek assistance, enrolling with Prescription Hope is the best way to have our team review your individual situation. Rozlytrek patient assistance eligibility and general prescription assistance eligibility are based on several common factors, including household income, insurance coverage, a valid prescription, and U.S. residency.
Income guidelines vary by program. When reviewing Rozlytrek assistance eligibility, each program applies its own household income limits and may consider factors such as family size and total annual income.
Insurance requirements also differ. Medication assistance qualifications may depend on whether you are uninsured or whether your current coverage does not adequately reduce the cost of your prescribed medication.
A valid prescription is required. As part of prescription assistance eligibility, qualified patients must have a current prescription from a licensed healthcare provider for the brand-name medication they are seeking through the program.
Applicants must meet U.S. residency requirements. Patient assistance programs generally require qualified patients to be legal residents of the United States and may request documentation to confirm residency as part of the eligibility review.
Simple Enrollment With Expert Support
Do you want help with your Rozlytrek assistance enrollment? Are you looking for Rozlytrek application support? Applying to Prescription Hope’s medication access service takes 6 simple steps:
- Submit Information: Take a few minutes to fill out our online enrollment form.
- Advocate Contact: After we review your enrollment form, a patient advocate will contact you in 1-2 business days.
- Document Collection: Our team will collect all necessary documents from you and your healthcare provider following prequalification.
- Provider Coordination: Our team will also gather any signatures needed from your healthcare provider.
- Program Submission: Once everything is in order, we will submit your application to the prescription assistance program and continue coordinating with your healthcare provider and the pharmaceutical manufacturer.
- Medication Delivery: Qualified patients should receive their name-brand medication 1-2 weeks after their application is cleared. Medications are shipped directly from the manufacturer to the patient’s door or doctor’s office.
Understanding Rozlytrek
How Rozlytrek Works
Rozlytrek contains entrectinib, which blocks the activity of several receptor tyrosine kinases, including TRKA, TRKB, TRKC, ROS1, and ALK. Certain cancers can be driven by abnormal activation of these signaling pathways, and entrectinib can interfere with signaling that promotes cancer-cell proliferation.
In simple terms, Rozlytrek targets specific abnormal signals that can drive certain cancers, particularly cancers containing ROS1 or NTRK gene alterations.
What Conditions Does Rozlytrek Treat?
Rozlytrek is approved for adults with ROS1-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. It is also approved for adults and pediatric patients older than 1 month with certain NTRK gene fusion-positive solid tumors that meet the specific requirements in the FDA-approved indication.
The NTRK indication applies when the tumor has an NTRK gene fusion without a known acquired resistance mutation, is metastatic or would require surgery likely to result in severe morbidity, and has progressed following treatment or has no satisfactory alternative therapy. This indication was approved under accelerated approval.
Benefits of Treatment
For appropriate patients, Rozlytrek provides a targeted treatment option based on specific genetic characteristics of a tumor. It may be used to treat ROS1-positive metastatic NSCLC and certain NTRK gene fusion-positive solid tumors, including in pediatric patients older than 1 month for the NTRK indication.
Important Safety Information and Side Effects
Congestive Heart Failure
Rozlytrek can cause congestive heart failure, including in patients without a previous history of heart failure. The FDA labeling recommends evaluating left ventricular ejection fraction before treatment and monitoring for clinical signs and symptoms of heart failure.
Central Nervous System Effects
Rozlytrek can cause central nervous system effects, including cognitive impairment, mood disorders, dizziness, and sleep disturbances. Depending on severity, treatment may need to be withheld, dose-reduced, or permanently discontinued.
Skeletal Fractures
Rozlytrek increases the risk of fractures. Patients who develop signs or symptoms of a fracture should receive prompt medical evaluation.
Hepatotoxicity
Rozlytrek can cause hepatotoxicity, including increases in liver enzymes. The FDA labeling recommends monitoring liver tests during treatment. Depending on the severity of abnormalities, treatment may need to be withheld, dose-reduced, or permanently discontinued.
Hyperuricemia
Rozlytrek can increase serum uric acid levels. Serum uric acid should be assessed before treatment and periodically during treatment, with patients monitored for signs and symptoms of hyperuricemia.
QT Interval Prolongation
Rozlytrek can cause QT interval prolongation, which can increase the risk of potentially serious abnormal heart rhythms. The FDA labeling recommends assessing the QT interval and electrolytes before treatment and periodically during treatment in appropriate patients.
Vision Disorders
Vision disorders can occur with Rozlytrek. The prescribing information recommends withholding treatment for new visual changes or changes that interfere with activities of daily living until improvement or stabilization.
Embryo-Fetal Toxicity
Rozlytrek can cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for at least 5 weeks after the last dose. Male patients with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the last dose.
Contraindications
The current FDA-approved prescribing information lists no contraindications for Rozlytrek.
Drug Interactions
Moderate and Strong CYP3A Inhibitors
Moderate and strong CYP3A inhibitors can increase entrectinib concentrations and potentially increase adverse reactions. The labeling recommends avoiding these medications when possible and provides dose-reduction guidance when their use cannot be avoided.
Moderate and Strong CYP3A Inducers
Moderate and strong CYP3A inducers can decrease entrectinib concentrations and may reduce Rozlytrek’s effectiveness. The FDA labeling recommends avoiding concomitant use.
Drugs That Prolong QTc
Rozlytrek can prolong the QT interval. The FDA labeling recommends avoiding concomitant use with other products known to have the potential to prolong the QT/QTc interval.
Grapefruit Products
Patients should avoid grapefruit products while taking Rozlytrek because grapefruit contains CYP3A inhibitors.
Pregnancy and Breastfeeding
Rozlytrek can cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for at least 5 weeks after the last dose. Male patients with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the last dose.
Because of the potential for serious adverse reactions in breastfed children, patients should discontinue breastfeeding during treatment and for 7 days after the last dose.
Common Side Effects
The most common adverse reactions occurring in 20% or more of patients include fatigue, constipation, changes in taste, edema, dizziness, diarrhea, nausea, abnormal touch sensations, shortness of breath, muscle pain, cognitive impairment, weight gain, cough, vomiting, fever, joint pain, and vision disorders.
Administration Information
Rozlytrek is taken orally once daily, with or without food. The recommended adult dosage is 600 mg once daily. Pediatric dosing for NTRK-positive solid tumors is based on age and body surface area.
Dosage Forms and Strengths
Rozlytrek is available as 100 mg and 200 mg capsules and 50 mg oral-pellet packets.
Access to Multiple Medications
Need multiple medication assistance or help with prescription costs?
Prescription Hope medication assistance helps qualified patients navigate medication assistance programs and secure prescription assistance for multiple medications at the same time. Whether you need coordinated access across several treatments or ongoing support, our dedicated team provides full-service assistance for a simple $70.00 per month, per medication.
Why Choose Prescription Hope for Rozlytrek Assistance?
Patient-Focused Medication Support
For two decades, Prescription Hope patient support has helped qualified patients navigate prescription costs with greater confidence. Our Florida-based medication access specialists and dedicated advocates deliver compassionate, patient-focused medication support and personalized medication assistance throughout the application process. Whether you need help understanding eligibility, organizing paperwork, or pursuing Rozlytrek patient assistance, our team manages the details so you can focus on your health and access the medication support you need.
Simplified Access to Specialty Therapies
At Prescription Hope, we help qualified patients pursue access to specialty medications with compassionate, personalized guidance. Our specialty medication assistance makes it easier to explore specialty therapy affordability and navigate prescription assistance for specialty therapies, including Rozlytrek specialty medication assistance. We manage the details so you can spend less time worrying about medication costs and more time focusing on your health and peace of mind.
Ongoing Prescription Assistance
Our ongoing prescription assistance extends beyond the initial application, giving qualified patients dependable, long-term medication support to help them stay on track with treatment. Through continued medication assistance, our dedicated patient advocates handle document and form updates, issue resolution, program monitoring, refill scheduling, and each prescription assistance renewal, making the process easier to manage over time.
If you are seeking a simpler way to access an affordable brand-name medication, Prescription Hope is here to help. Enroll today to explore Rozlytrek prescription assistance, and let our caring team guide you through the process, manage the important details, and make accessing your prescribed medication feel less overwhelming.